<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03651466</url>
  </required_header>
  <id_info>
    <org_study_id>GX-G6_HV1</org_study_id>
    <nct_id>NCT03651466</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of GX-G6 in Healthy Male Subjects</brief_title>
  <official_title>A First-in-Human, Single Ascending Dose, Phase 1, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Subcutaneously Administered GX-G6 in Male Healthy Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genexine, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genexine, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single-center, double-blind, placebo-controlled, phase I study with healthy
      male subjects receiving ascending single s.c. doses of GX-G6
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A screening examination will be performed within 28 days prior to dosing. Eligible subjects
      will return to the study center in the morning of Day -1 and will remain in-patient until
      discharge about 98 hours after dosing (after oral glucose tolerance test in the morning of
      Day 5) if there are no safety issues. The s.c. injection will be administered in the morning
      of Day 1. Ambulatory visits will take place on Days 7, 9 and 12. A follow-up visit will take
      place on Day 15 and a final visit on Day 28.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 31, 2017</start_date>
  <completion_date type="Actual">June 28, 2018</completion_date>
  <primary_completion_date type="Actual">June 6, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence, nature and severity of Adverse events</measure>
    <time_frame>Throughout 4 weeks of study</time_frame>
    <description>All safety data will be evaluated descriptively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics(PD) variables</measure>
    <time_frame>Pre-dose and 24, 48, 72, 96, 144, 192, 264 and 336 hours after dosing</time_frame>
    <description>Oral glucose tolerance test in mol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics(PK) variables</measure>
    <time_frame>Pre-dose and 24, 48, 72, 96, 144, 192, 264 and 336 hours after dosing</time_frame>
    <description>GX-G6 concentration in blood</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Cohort 1: GX-G6 + placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of pre-determined dose (Level I) GX-G6 (6 subjects) and pre-determined dose (Level I) placebo (2 subjects)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: GX-G6 + placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of pre-determined dose (Level II) GX-G6 (6 subjects) and pre-determined dose (Level II) placebo (2 subjects)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: GX-G6 + placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of pre-determined dose (Level III) GX-G6 (6 subjects) and pre-determined dose (Level III) placebo (2 subjects)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: GX-G6 + placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of pre-determined dose (Level IV) GX-G6 (6 subjects) and pre-determined dose (Level IV) placebo (2 subjects)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(Optional) Cohort 5: GX-G6 + placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of pre-determined dose (Level V) GX-G6 (6 subjects) and pre-determined dose (Level V) placebo (2 subjects)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(Optional) Cohort 6: GX-G6 + placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single administration of pre-determined dose (Level VI) GX-G6 (6 subjects) and pre-determined dose (Level VI) placebo (2 subjects)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gx-G6</intervention_name>
    <description>Each subject will receive a single dose of either GX-G6 or placebo in randomized fashion.</description>
    <arm_group_label>(Optional) Cohort 5: GX-G6 + placebo</arm_group_label>
    <arm_group_label>(Optional) Cohort 6: GX-G6 + placebo</arm_group_label>
    <arm_group_label>Cohort 1: GX-G6 + placebo</arm_group_label>
    <arm_group_label>Cohort 2: GX-G6 + placebo</arm_group_label>
    <arm_group_label>Cohort 3: GX-G6 + placebo</arm_group_label>
    <arm_group_label>Cohort 4: GX-G6 + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Each subject will receive a single dose of either GX-G6 or placebo in randomized fashion.</description>
    <arm_group_label>(Optional) Cohort 5: GX-G6 + placebo</arm_group_label>
    <arm_group_label>(Optional) Cohort 6: GX-G6 + placebo</arm_group_label>
    <arm_group_label>Cohort 1: GX-G6 + placebo</arm_group_label>
    <arm_group_label>Cohort 2: GX-G6 + placebo</arm_group_label>
    <arm_group_label>Cohort 3: GX-G6 + placebo</arm_group_label>
    <arm_group_label>Cohort 4: GX-G6 + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. male subjects aged between 18-50 years (both inclusive)

          2. healthy subjects as determined by medical history, physical examination including
             vital signs, ECG and clinical laboratory testing

          3. subjects who are able and willing to give written informed consent

          4. male subjects must be using 2 acceptable methods for contraception (one of these
             methods should be a barrier method e.g. spermicide and condom) from start of dosing
             and refrain from fathering a child in the 3 months following dosing.

        Exclusion Criteria:

        History of:

          1. clinically relevant allergy (except for untreated, asymptomatic, seasonal allergies at
             time of dosing), especially allergy to macrolide antibiotics;

          2. any clinically significant pancreatic, hepatic, renal, gastrointestinal,
             cardiovascular, respiratory, hematological, central nervous system diseases or other
             significant diseases which might influence either the safety of the subject or the
             absorption, metabolism or excretion of the active agent under investigation;

          3. diabetes mellitus and thyroid dysfunction or other endocrine disorders;

          4. malignancy;

          5. substance abuse or addiction (alcohol, drugs) in the past 3 years.

             Present Condition:

          6. participation in a clinical investigation within the 30 days prior to the planned
             first drug administration or during this trial;

          7. participation in this study at a previous dose level;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>mi-sun byun, Ph. D</last_name>
    <role>Study Director</role>
    <affiliation>Genexine, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NUVISAN</name>
      <address>
        <city>Neu-Ulm</city>
        <zip>89231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 5, 2018</study_first_submitted>
  <study_first_submitted_qc>August 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2018</study_first_posted>
  <last_update_submitted>August 27, 2018</last_update_submitted>
  <last_update_submitted_qc>August 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

